Do analysts prefer QNCX or BNR?

Quince Therapeutics presently has a consensus price target of $260.00, suggesting a potential upside of 779.86%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Quince Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.42 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ENGN or QNCX?

enGene is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$1.13 N/A Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A

Is ENGN or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -27.97% -22.65% Quince Therapeutics N/A N/A -133.84%

Is QNCX or BDTX more profitable?

Quince Therapeutics' return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -133.84% Black Diamond Therapeutics N/A -32.10% -25.21%

Is QNCX or CBUS more profitable?

Quince Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Quince Therapeutics' return on equity of 0.00% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -133.84% Cibus -2,258.89% -287.03% -27.99%

Is RANI or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -104.60% -65.17% Quince Therapeutics N/A N/A -133.84%

Quince Therapeutics (QNCX) Competitors

$29.55 +0.59 (+2.04%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$29.50 -0.05 (-0.15%)

As of 09/11/2026 07:30 PM Eastern

Compare

QNCX vs. BNR, ENGN, BDTX, CBUS, and RANI

Should you buy Quince Therapeutics stock or one of its competitors? Quince Therapeutics's main competitors and comparable companies include Burning Rock Biotech (BNR), enGene (ENGN), Black Diamond Therapeutics (BDTX), Cibus (CBUS), and Rani Therapeutics (RANI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Quince Therapeutics compare to Burning Rock Biotech?

Quince Therapeutics (NASDAQ:QNCX) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Quince Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

Quince Therapeutics presently has a consensus price target of $260.00, suggesting a potential upside of 779.86%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Quince Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.42
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Burning Rock Biotech has higher revenue and earnings than Quince Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Burning Rock Biotech	$77.16M	1.67	-$7.92M	-$0.87	N/A

In the previous week, Burning Rock Biotech had 4 more articles in the media than Quince Therapeutics. MarketBeat recorded 5 mentions for Burning Rock Biotech and 1 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.87 beat Burning Rock Biotech's score of 0.63 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Quince Therapeutics	Very Positive
Burning Rock Biotech	Positive

Quince Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. Quince Therapeutics' return on equity of 0.00% beat Burning Rock Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Burning Rock Biotech	-13.60%	-12.86%	-8.51%

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 5.6% of Quince Therapeutics shares are owned by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Quince Therapeutics beats Burning Rock Biotech on 9 of the 16 factors compared between the two stocks.

How does Quince Therapeutics compare to enGene?

enGene (NASDAQ:ENGN) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

64.2% of enGene shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 10.5% of enGene shares are held by company insiders. Comparatively, 5.6% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

enGene currently has a consensus target price of $11.05, suggesting a potential upside of 513.64%. Quince Therapeutics has a consensus target price of $260.00, suggesting a potential upside of 779.86%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.42

enGene has a beta of -0.28, indicating that its share price is 128% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

In the previous week, enGene had 26 more articles in the media than Quince Therapeutics. MarketBeat recorded 27 mentions for enGene and 1 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.87 beat enGene's score of 0.28 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
enGene	Neutral
Quince Therapeutics	Very Positive

enGene is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$1.13	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

Quince Therapeutics' return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-27.97%	-22.65%
Quince Therapeutics	N/A	N/A	-133.84%

Summary

Quince Therapeutics beats enGene on 8 of the 14 factors compared between the two stocks.

How does Quince Therapeutics compare to Black Diamond Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Quince Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.31, indicating that its share price is 231% more volatile than the broader market.

Black Diamond Therapeutics has higher revenue and earnings than Quince Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Black Diamond Therapeutics	$70M	1.63	$22.37M	-$0.75	N/A

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 5.6% of Quince Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Quince Therapeutics. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 1 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.87 beat Black Diamond Therapeutics' score of 1.79 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Quince Therapeutics	Very Positive
Black Diamond Therapeutics	Very Positive

Quince Therapeutics presently has a consensus target price of $260.00, suggesting a potential upside of 779.86%. Black Diamond Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 417.68%. Given Quince Therapeutics' higher probable upside, research analysts plainly believe Quince Therapeutics is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.42
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Quince Therapeutics' return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

Summary

Black Diamond Therapeutics beats Quince Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Quince Therapeutics compare to Cibus?

Quince Therapeutics (NASDAQ:QNCX) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

In the previous week, Cibus had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 2 mentions for Cibus and 1 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.87 beat Cibus' score of 0.93 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Quince Therapeutics	Very Positive
Cibus	Positive

Quince Therapeutics presently has a consensus price target of $260.00, indicating a potential upside of 779.86%. Cibus has a consensus price target of $9.00, indicating a potential upside of 473.25%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Quince Therapeutics is more favorable than Cibus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.42
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 33.8% of Cibus shares are owned by institutional investors. 5.6% of Quince Therapeutics shares are owned by insiders. Comparatively, 29.9% of Cibus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Quince Therapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Cibus has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

Quince Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Quince Therapeutics' return on equity of 0.00% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Cibus	-2,258.89%	-287.03%	-27.99%

Quince Therapeutics has higher earnings, but lower revenue than Cibus. Cibus is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Cibus	$3.64M	32.97	-$127.08M	-$1.65	N/A

Summary

Quince Therapeutics beats Cibus on 9 of the 16 factors compared between the two stocks.

How does Quince Therapeutics compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by company insiders. Comparatively, 5.6% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Quince Therapeutics' return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
Quince Therapeutics	N/A	N/A	-133.84%

Rani Therapeutics has higher revenue and earnings than Quince Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	72.06	-$29.67M	-$0.27	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

Rani Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 938.45%. Quince Therapeutics has a consensus target price of $260.00, suggesting a potential upside of 779.86%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Rani Therapeutics is more favorable than Quince Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.42

Rani Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

In the previous week, Rani Therapeutics had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 2 mentions for Rani Therapeutics and 1 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.87 beat Rani Therapeutics' score of 0.94 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Rani Therapeutics	Positive
Quince Therapeutics	Very Positive

Summary

Rani Therapeutics beats Quince Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Quince Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNCX vs. The Competition

Export

Metric	Quince Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$30.06M	$3.85B	$7.15B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-0.19	14.18	274.94	25.36
Price / Sales	N/A	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	-0.23	15.12	10.33	6.20
Net Income	-$83.98M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-5.65%	-4.34%	-3.32%	-2.35%
1 Month Performance	-8.82%	0.54%	-0.53%	-3.23%
1 Year Performance	-90.77%	40.74%	23.51%	8.79%

Quince Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNCX Quince Therapeutics	3.3851 of 5 stars	$29.55 +2.0%	$260.00 +779.9%	-90.8%	$30.06M	N/A	N/A	60	Positive News
BNR Burning Rock Biotech	0.9425 of 5 stars	$11.99 flat	N/A	+44.6%	$126.11M	$77.16M	N/A	1,390	News Coverage Earnings Report Analyst Upgrade High Trading Volume
ENGN enGene	4.0793 of 5 stars	$1.82 flat	$11.05 +506.9%	-68.5%	$121.91M	N/A	N/A	31	Trending News Earnings Report Analyst Forecast Analyst Revision
BDTX Black Diamond Therapeutics	2.9016 of 5 stars	$2.12 flat	$10.25 +383.5%	-39.1%	$121.80M	$70M	N/A	90
CBUS Cibus	1.6024 of 5 stars	$1.59 flat	$9.00 +466.0%	+15.4%	$121.52M	$3.64M	N/A	48

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNCX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quince Therapeutics (QNCX) Competitors

QNCX vs. BNR, ENGN, BDTX, CBUS, and RANI

How does Quince Therapeutics compare to Burning Rock Biotech?

Summary

How does Quince Therapeutics compare to enGene?

Summary

How does Quince Therapeutics compare to Black Diamond Therapeutics?

Summary

How does Quince Therapeutics compare to Cibus?

Summary

How does Quince Therapeutics compare to Rani Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quince Therapeutics (QNCX) Competitors

QNCX vs. BNR, ENGN, BDTX, CBUS, and RANI

How does Quince Therapeutics compare to Burning Rock Biotech?

Which has more volatility & risk, QNCX or BNR?

Do analysts prefer QNCX or BNR?

Which has preferable earnings and valuation, QNCX or BNR?

Does the media favor QNCX or BNR?

Is QNCX or BNR more profitable?

Do insiders and institutionals have more ownership in QNCX or BNR?

Summary

How does Quince Therapeutics compare to enGene?

Do institutionals & insiders have more ownership in ENGN or QNCX?

Do analysts recommend ENGN or QNCX?

Which has more volatility and risk, ENGN or QNCX?

Does the media prefer ENGN or QNCX?

Which has preferable earnings & valuation, ENGN or QNCX?

Is ENGN or QNCX more profitable?

Summary

How does Quince Therapeutics compare to Black Diamond Therapeutics?

Which has more risk & volatility, QNCX or BDTX?

Which has better earnings & valuation, QNCX or BDTX?

Do insiders and institutionals hold more shares of QNCX or BDTX?

Does the media refer more to QNCX or BDTX?

Do analysts rate QNCX or BDTX?

Is QNCX or BDTX more profitable?

Summary

How does Quince Therapeutics compare to Cibus?

Does the media favor QNCX or CBUS?

Do analysts rate QNCX or CBUS?

Do institutionals and insiders hold more shares of QNCX or CBUS?

Which has more volatility and risk, QNCX or CBUS?

Is QNCX or CBUS more profitable?

Which has higher earnings and valuation, QNCX or CBUS?

Summary

How does Quince Therapeutics compare to Rani Therapeutics?

Do institutionals & insiders hold more shares of RANI or QNCX?

Is RANI or QNCX more profitable?

Which has higher earnings and valuation, RANI or QNCX?

Do analysts rate RANI or QNCX?

Which has more volatility & risk, RANI or QNCX?

Does the media prefer RANI or QNCX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools